ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA RETINOPATHY OF PREMATURITY

Abstract

Introduction : Vascular endothelial growth factor (VEGF) is an important mediator of pathological neovascularization and ocular vascular permeability. In phase I ROP, VEGF levels decrease due to hyperoxia but increase sharply in phase II ROP due to hypoxia, which triggers retinal neovascularization. Purpose : T o increase understanding of anti-VEGF injection therapy as a management for ROP in order to avoid serious complications such as blindness in children. R esult : T he use of intravitreal therapy targeting VEGF is increasingly in demand and has changed the way of view in treating vitreoretinal disease in children, especially in cases with severe posterior abnormalities , media opacity, and unstable systemic Compared with laser , anti-VEGF allows retinal vasculature to further vascularize toward the peripheral retina . Conclusion : Although it has many advantages, it is necessary to have a good understanding and continuous observation of systemic side effects and long-term neurodevelopment in children after anti-VEGF injection given that this action is a new therapy compared to others.